G92.0
Immune effector cell-associated neurotoxicity syndrome
Clinical Classification Guidelines
Code First
- underlying cause such as:
- complications of immune effector cellular therapy (T80.82)
Code Also
- , if applicable, associated signs and symptoms, such as:
- cerebral edema (G93.6)
- unspecified convulsions (R56.9)
Medical Intelligence & Overview
Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) is a neurological complication that can occur after certain types of immunotherapy, particularly treatments involving immune effector cells like CAR T-cell therapy. This condition is characterized by a range of neurological symptoms that can vary from mild to severe. Recognizing the signs and understanding the potential impacts of ICANS are crucial for healthcare providers managing patients undergoing immunotherapy.
Causes & Symptoms
Clinical Causes: Administration of immune effector cell therapies such as CAR T-cell therapy The activation of immune cells targeting cancer or other disease cells Cytokine release syndrome (CRS), which often occurs concurrently and may contribute to neurotoxicity Inflammatory responses in the brain caused by immune system activation Patient-specific factors, including underlying health conditions and immune system status
Key Symptoms: Altered mental status, confusion, or decreased consciousness Headache or dizziness Nausea and vomiting Seizures Difficulty speaking or understanding speech Weakness or paralysis in limbs Fever or chills (may indicate concurrent infections or cytokine release syndrome) Visual disturbances or changes in perception
Diagnostic & Treatment
Diagnosis Path: The diagnosis of ICANS involves a comprehensive neurological assessment combined with laboratory and imaging studies. Healthcare providers typically evaluate symptoms, perform neurological examinations, and may order tests such as MRI scans or EEGs to assess brain activity. Blood tests to measure cytokine levels and markers of inflammation are also common. Because symptoms can overlap with other conditions, ruling out infections, metabolic disturbances, or other neurological disorders is a key step in diagnosis.
Treatment Protocols: Managing ICANS generally requires a multidisciplinary approach. The primary goal is to control inflammation and support neurological function. Treatment strategies may include:
Clinical Advice & FAQs
Billing Guidance
Is G92.0 a billable ICD-10 code?
Yes, G92.0 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report G92.0?
Clinical documentation must specify the nature of Immune effector cell-associated neurotoxicity syndrome and any associated comorbidities for accurate reporting.
Cite this Clinical Reference